Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC

NCT07050043 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

123

Enrollment

OTHER_GOV

Sponsor class

Conditions

NSCLC (Non-small Cell Lung Carcinoma)
First Line Therapy
Locally Advanced/Metastatic NSCLC

Interventions

DRUG: Nivolumab 40mg
DRUG: Cisplatin, Carboplatin, Pemetrexed, Gemcitabine, Paclitaxel, Docetaxel

Sponsor

Dr Arvindran A/L Alaga